financetom
Business
financetom
/
Business
/
Affinity Bancshares' Q3 profit rises on interest income growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Affinity Bancshares' Q3 profit rises on interest income growth
Oct 24, 2025 2:04 PM

Overview

* Affinity Bancshares ( AFBI ) Q3 net income rises to $2.2 mln from $1.7 mln year-over-year

* Company's Q3 net interest income increases to $7.8 mln from $7.4 mln year-over-year

* Net interest margin for Q3 decreases to 3.49% from 3.52% year-over-year

Outlook

* Company did not provide specific guidance for future quarters or full year in press release

Result Drivers

* NET INTEREST INCOME - Increase in net interest income due to higher interest income on loans and deposits, partially offset by higher deposit costs

* NONINTEREST EXPENSES - Decrease in noninterest expenses mainly due to lower other fees

* LOAN GROWTH - Steady demand in construction, consumer, and commercial real estate loans

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $0.34

Q3 Net $2.21

Income mln

Q3 Net $7.77

Interest mln

Income

Q3 Net 3.49%

Interest

Margin

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dr. Reddy's Laboratories' Atomoxetine Hydrochloride Capsules Suspended in China
Dr. Reddy's Laboratories' Atomoxetine Hydrochloride Capsules Suspended in China
Sep 3, 2024
10:06 AM EDT, 09/03/2024 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) said in a regulatory filing Tuesday that China's National Medical Products Administration has issued an order suspending the import, sale, and use of the company's atomoxetine hydrochloride capsules, effective Aug. 30, for failing to meet the country's good manufacturing practice standards. China's National Drug Joint Procurement Office has also...
UL Solutions Launches Secondary Offering of Common Shares
UL Solutions Launches Secondary Offering of Common Shares
Sep 3, 2024
04:44 PM EDT, 09/03/2024 (MT Newswires) -- UL Solutions ( ULS ) said Tuesday it has started an underwritten public offering of 20 million class A shares. The offering comprises shares to be sold by selling shareholder UL Standards & Engagement, UL Solutions ( ULS ) said. The underwriters will have a 30-day option to buy up to an additional...
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
Sep 3, 2024
On Tuesday, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Moderna, Inc ( MRNA ).‘s  updated COVID-19 vaccine, which targets the JN.1 variant of SARS-CoV-2. Following the MHRA decision, doses will be available for eligible groups as part of the NHS autumn vaccination program, which is prioritized for use in people at greatest risk of serious illness from COVID-19....
Sezzle Insider Sold Shares Worth $439,805, According to a Recent SEC Filing
Sezzle Insider Sold Shares Worth $439,805, According to a Recent SEC Filing
Sep 3, 2024
04:09 PM EDT, 09/03/2024 (MT Newswires) -- Paul Paradis, Director, Executive Director & President, on August 30, 2024, sold 3,290 shares in Sezzle ( SEZL ) for $439,805. Following the Form 4 filing with the SEC, Paradis has control over a total of 173,112 shares of the company, with 173,112 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1662991/000166299124000246/xslF345X05/wk-form4_1725393863.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved